Tohoku University Tohoku Medical Megabank Organization (Eiichi N. Kodama)
2020.05.29

1.   Hozawa Atsushi, Tanno Kozo, Nakaya Naoki, et al. Study profile of The Tohoku Medical Megabank Community-Based Cohort Study. Journal of epidemiology. 2020; : . doi:10.2188/jea.JE20190271  
2.   Tsukada Kento, Shinki Shono, Kaneko Akiho, et al. Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications. 2020; 11 (1): 1830. doi:10.1038/s41467-020-15664-4  
3.   Oe Chihiro, Hayashi Hironori, Hirata Kazushige, et al. Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins. ACS Infectious Diseases. 2019; : acsinfecdis.9b00305. doi:10.1021/acsinfecdis.9b00305  
4.   Kikuchi Haruhisa, Kawai Kosuke, Nakashiro Yota, et al. Construction of a Meroterpenoid-Like Compounds Library Based on Diversity-Enhanced Extracts. Chemistry (Weinheim an der Bergstrasse, Germany). 2019; 25 (4): 1106-1112. doi:10.1002/chem.201805417  
5.   Kuriyama Shinichi, Metoki Hirohito, Kikuya Masahiro, et al. Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): Rationale, Progress and Perspective. International Journal of Epidemiology. 2019; : . doi:10.1093/ije/dyz169  
6.   Siarot Lowela, Chutiwitoonchai Nopporn, Sato Hirotaka, et al. Identification of human immunodeficiency virus type-1 Gag-TSG101 interaction inhibitors by high-throughput screening. Biochemical and biophysical research communications. 2018; 503 (4): 2970-2976. doi:10.1016/j.bbrc.2018.08.079  
7.   Watanabe Masahiro, Hashimoto Koichi, Abe Yusaku, et al. A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. PLOS ONE. 2016; 11 (9): e0162823. doi:10.1371/journal.pone.0162823  
8.   Salie Zhe Li, Kirby Karen A., Michailidis Eleftherios, et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences. 2016; 113 (33): 9274-9279. doi:10.1073/pnas.1605223113  
9.   Miyamoto Fusako, Kawaji Kumi, Oishi Shinya, et al. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method. Antiviral chemistry & chemotherapy. 2015; 24 (2): 77-82. doi:10.1177/2040206615614164  
10.   Asai Teigo, Tsukada Kento, Ise Satomi, et al. Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. Nature Chemistry. 2015; 7 (9): 737-743. doi:10.1038/nchem.2308  
11.   Maeda Kenji, Desai Darshan V, Aoki Manabu, et al. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antiviral therapy. 2014; 19 (2): 179-89. doi:10.3851/IMP2697  
12.   Hachiya Atsuko, Reeve Aaron B, Marchand Bruno, et al. Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy. 2013; 57 (9): 4554-4558. doi:10.1128/AAC.00283-13  
13.   Shimane Kazuki, Kawaji Kumi, Miyamoto Fusako, et al. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains. Antimicrobial agents and chemotherapy. 2013; 57 (8): 4035-8. doi:10.1128/AAC.00237-13